Literature DB >> 22573806

MAPK regulation of IL-4/IL-13 receptors contributes to the synergistic increase in CCL11/eotaxin-1 in response to TGF-β1 and IL-13 in human airway fibroblasts.

Xiuxia Zhou1, Haizhen Hu, Silvana Balzar, John B Trudeau, Sally E Wenzel.   

Abstract

CCL11/eotaxin-1 is a potent eosinophilic CC chemokine expressed by primary human fibroblasts. The combination of TGF-β1 and IL-13 synergistically increases CCL11 expression, but the mechanisms behind the synergy are unclear. To address this, human airway fibroblast cultures from normal and asthmatic subjects were exposed to IL-13 alone or TGF-β1 plus IL-13. Transcriptional (nuclear run-on) and posttranscriptional (mRNA stability) assays confirmed that transcriptional regulation is critical for synergistic expression of CCL11. TGF-β1 plus IL-13 synergistically increased STAT-6 phosphorylation, nuclear translocation, and binding to the CCL11 promoter as compared with IL-13 alone. STAT-6 small interfering RNA significantly knocked down both STAT-6 mRNA expression and phosphorylation and inhibited CCL11 mRNA and protein expression. Regulation of the IL-4Rα complex by TGF-β1 augmented IL-13 signaling by dampening IL-13Rα2 expression, overcoming IL-13's autoregulation of its pathway and enhancing the expression of CCL11. Our data suggest that TGF-β1 induced activation of the MEK/ERK pathway reduces IL-13Rα2 expression induced by IL-13. Thus, TGF-β1, a pleiotropic cytokine upregulated in asthmatic airways, can augment eosinophilic inflammation by interfering with IL-13's negative feedback autoregulatory loop under MEK/ERK-dependent conditions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22573806      PMCID: PMC3370069          DOI: 10.4049/jimmunol.1102760

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA.

Authors:  Matt K Lee; Cécile Pardoux; Marie C Hall; Pierre S Lee; David Warburton; Jing Qing; Susan M Smith; Rik Derynck
Journal:  EMBO J       Date:  2007-08-02       Impact factor: 11.598

Review 2.  Cytokines and growth factors in airway remodeling in asthma.

Authors:  Taylor Doherty; David Broide
Journal:  Curr Opin Immunol       Date:  2007-08-27       Impact factor: 7.486

3.  IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: a role for ERK.

Authors:  Paul E Moore; Trudi L Church; David D Chism; Reynold A Panettieri; Stephanie A Shore
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-04       Impact factor: 5.464

4.  TGF-beta and IL-13 synergistically increase eotaxin-1 production in human airway fibroblasts.

Authors:  Sally E Wenzel; John B Trudeau; Steve Barnes; XiuXia Zhou; Meghan Cundall; Jay Y Westcott; Kelly McCord; Hong Wei Chu
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

5.  Selective induction of eotaxin release by interleukin-13 or interleukin-4 in human airway smooth muscle cells is synergistic with interleukin-1beta and is mediated by the interleukin-4 receptor alpha-chain.

Authors:  Stuart J Hirst; Matthew P Hallsworth; Qi Peng; Tak H Lee
Journal:  Am J Respir Crit Care Med       Date:  2002-04-15       Impact factor: 21.405

6.  Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways.

Authors:  Jaspreet Pannu; Sashidhar Nakerakanti; Edwin Smith; Peter ten Dijke; Maria Trojanowska
Journal:  J Biol Chem       Date:  2007-02-15       Impact factor: 5.157

7.  Analysis of the life cycle of stat6. Continuous cycling of STAT6 is required for IL-4 signaling.

Authors:  Ryan P Andrews; Mark B Ericksen; Christie M Cunningham; Michael O Daines; Gurjit K Khurana Hershey
Journal:  J Biol Chem       Date:  2002-07-16       Impact factor: 5.157

8.  Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis.

Authors:  Richard Ahrens; Amanda Waddell; Luqman Seidu; Carine Blanchard; Rebecca Carey; Elizabeth Forbes; Maria Lampinen; Tara Wilson; Elizabeth Cohen; Keith Stringer; Edgar Ballard; Ariel Munitz; Huan Xu; Nancy Lee; James J Lee; Marc E Rothenberg; Lee Denson; Simon P Hogan
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

9.  Mepolizumab and exacerbations of refractory eosinophilic asthma.

Authors:  Pranabashis Haldar; Christopher E Brightling; Beverley Hargadon; Sumit Gupta; William Monteiro; Ana Sousa; Richard P Marshall; Peter Bradding; Ruth H Green; Andrew J Wardlaw; Ian D Pavord
Journal:  N Engl J Med       Date:  2009-03-05       Impact factor: 91.245

10.  IFN-gamma, IL-4 and IL-13 modulate responsiveness of human airway smooth muscle cells to IL-13.

Authors:  Barry J Moynihan; Barbara Tolloczko; Souad El Bassam; Pascale Ferraro; Marie-Claire Michoud; James G Martin; Sophie Laberge
Journal:  Respir Res       Date:  2008-12-30
View more
  18 in total

1.  Commentary: IL-4 and IL-13 receptors and signaling.

Authors:  Sarah M McCormick; Nicola M Heller
Journal:  Cytokine       Date:  2015-07-14       Impact factor: 3.861

Review 2.  An Overlook to the Characteristics and Roles Played by Eotaxin Network in the Pathophysiology of Food Allergies: Allergic Asthma and Atopic Dermatitis.

Authors:  Zahra Ahmadi; Gholamhossein Hassanshahi; Hossein Khorramdelazad; Nahid Zainodini; Leila Koochakzadeh
Journal:  Inflammation       Date:  2016-06       Impact factor: 4.092

3.  Angiotensin-(1-7) attenuates airway remodelling and hyperresponsiveness in a model of chronic allergic lung inflammation.

Authors:  G S Magalhães; M G Rodrigues-Machado; D Motta-Santos; A R Silva; M V Caliari; L O Prata; S C Abreu; P R M Rocco; L S Barcelos; R A S Santos; M J Campagnole-Santos
Journal:  Br J Pharmacol       Date:  2015-03-18       Impact factor: 8.739

4.  Interleukin-13 induces collagen type-1 expression through matrix metalloproteinase-2 and transforming growth factor-β1 in airway fibroblasts in asthma.

Authors:  Rafael Firszt; Dave Francisco; Tony D Church; Joseph M Thomas; Jennifer L Ingram; Monica Kraft
Journal:  Eur Respir J       Date:  2013-05-16       Impact factor: 16.671

Review 5.  Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types.

Authors:  Xuan Ou; Heather A O'Leary; Hal E Broxmeyer
Journal:  Blood       Date:  2013-05-01       Impact factor: 22.113

6.  Leukotriene enhanced allergic lung inflammation through induction of chemokine production.

Authors:  Kihyuk Shin; Jung Joo Hwang; Bo-In Kwon; Farrah Kheradmand; David B Corry; Seung-Hyo Lee
Journal:  Clin Exp Med       Date:  2014-06-13       Impact factor: 5.057

7.  NF-κB perturbation reveals unique immunomodulatory functions in Prx1+ fibroblasts that promote development of atopic dermatitis.

Authors:  Kang I Ko; Jean J Merlet; Brett P DerGarabedian; Huang Zhen; Yoko Suzuki-Horiuchi; Matthew L Hedberg; Eileen Hu; Anh T Nguyen; Stephen Prouty; Faizan Alawi; Matthew C Walsh; Yongwon Choi; Sarah E Millar; Ashley Cliff; Jonathon Romero; Michael R Garvin; John T Seykora; Daniel Jacobson; Dana T Graves
Journal:  Sci Transl Med       Date:  2022-02-02       Impact factor: 19.319

8.  Acanthamoeba protease activity promotes allergic airway inflammation via protease-activated receptor 2.

Authors:  Mi Kyung Park; Min Kyoung Cho; Shin Ae Kang; Hye-Kyung Park; Dong-Hee Kim; Hak Sun Yu
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

9.  Gene expression profiling following NRF2 and KEAP1 siRNA knockdown in human lung fibroblasts identifies CCL11/Eotaxin-1 as a novel NRF2 regulated gene.

Authors:  Jimmy Fourtounis; I-Ming Wang; Marie-Claude Mathieu; David Claveau; Tenneille Loo; Aimee L Jackson; Mette A Peters; Alex G Therien; Yves Boie; Michael A Crackower
Journal:  Respir Res       Date:  2012-10-12

10.  IL-13 receptor α2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice.

Authors:  Mian Xie; Xiao-jun Wu; Jin-jun Zhang; Chao-sheng He
Journal:  Oncotarget       Date:  2015-10-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.